Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955081 | 0.93 | ESR1 (0.33) | CYP3A4TSHRMAPK1ESR1ALDH1A1 | |
| SCHEMBL19311682 | 0.76 | GPR3 (0.32) | — | |
| SCHEMBL25606316 | 0.76 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1NPC1RAB9A | |
| SCHEMBL10052130 | 0.76 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ESR1ALDH1A1 | |
| SCHEMBL20220230 | 0.76 | GPR3 (0.32) | — | |
| SCHEMBL39444 | 0.76 | TSHR (0.57) | CYP3A4TSHRMAPK1NPC1RAB9A | |
| SCHEMBL8109982 | 0.76 | TSHR (0.57) | CYP3A4TSHRMAPK1NPC1RAB9A | |
| SCHEMBL31498545 | 0.71 | TSHR (0.53) | CYP3A4TSHRMAPK1NPC1RAB9A | |
| SCHEMBL30336851 | 0.71 | TSHR (0.53) | CYP3A4TSHRMAPK1NPC1RAB9A | |
| SCHEMBL5180999 | 0.71 | TSHR (0.53) | CYP3A4TSHRMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| CN-106660953-A | High heat monomers and methods of use thereof | 沙特基础工业全球技术有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106536589-A | High heat monomer and method of use thereof | 沙特基础工业全球技术有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-8119764-B2 | Medical devices made of a polymer material | SOLVAY ADVANCED POLYMERS, L.L.C. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090082539-A1 | Medical devices made of a polymer material | SOLVAY ADVANCED POLYMERS, L.L.C. (US) | 2009-03-26 | — | — | US | disclosed |
| US-5481049-A | REACTING CONJUGATED DIENE AND WATER IN PRESENCE OF CARBON DIOXIDE, USING PALLADIUM COMPOUND AND A FREE PHOSPHINE AS CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | CYP3A4 1684/4885TSHR 3398/4885MAPK1 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.